Brief: Seelos Therapeutics Announces Dosing Of The First Participants In Trial Of SLS-005
28/02/2022 13:54
Feb 28 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES DOSING OF THE FIRST
PARTICIPANTS
IN A REGISTRATIONAL PHASE II/III TRIAL OF SLS-005 IN AMYOTROPHIC
LATERAL SCLEROSIS ON THE HEALEY ALS PLATFORM
Source text for Eikon: ID:nPn6Sf5lpa
Further company coverage: SEEL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio